The HAMA bank is an initiative aimed at collecting, preparing, and storing biological samples from patients treated for malignant hypertension and included in the HAMA cohort. Conducted under CRB (ISO20387) conditions, this biobank serves as an essential resource for understanding the disease's pathophysiology, as well as for identifying novel biomarkers and therapeutic targets

Start Date15 Jun 2025

Sponsor / Collaborator

Centre Hospitalier de Pau

NCT06459609

/ RecruitingNot ApplicableIIT

Effect of Protein Supplementation on Craving in Subjects Hospitalised for Addiction Treatment. Monocentric Pilot Study.

Moncentric pilot study conducted in the addictology department of the Pau Hospital, designed to demonstrate the benefit of protein supplementation on craving in patients with a substance use disorder at the start of their treatment for addiction.
This study will be conducted according a crossover design with a one-week phase with protein supplementation (P) and a one-week phase without protein supplementation (SP).

Start Date01 Oct 2024

Sponsor / Collaborator

Centre Hospitalier de Pau

NCT06193785

/ CompletedNot ApplicableIIT

Evaluation of Hypnosis Practice During a Semi-invasive and Painful Medical Examination in Neurology: the Electromyogram

Electromyogram is a current exam usually in neurological practices use for study peripheral nervous system. This is a semi-invasive examination causing pain. The aim of the study is to evaluate hypnosis practice in patients during an electromyogram. The investigator will evaluate pain with quantitative and qualitative evaluation in two groups with and without hypnosis in an open, quasi-randomised prospective therapeutic study in Pau hospital centre

Start Date25 Mar 2024

Sponsor / Collaborator

Centre Hospitalier de Pau

100 Clinical Results associated with Centre Hospitalier de Pau

0 Patents (Medical) associated with Centre Hospitalier de Pau

151

Literatures (Medical) associated with Centre Hospitalier de Pau

01 Dec 2024·Orthopaedics & Traumatology: Surgery & Research

Percutaneous arthroscopically assisted cheilectomy combined to percutaneous proximal phalanx osteotomy in hallux rigidus: Clinical and radiological outcomes in 30 feet at a 48-month follow-up

Article

Author: Laffenetre, Olivier ; Lebecque, Johan ; Lucas Y Hernandez, Julien ; Di Nallo, Martin

BACKGROUNDHallux rigidus is a degenerative condition affecting the middle age population. It affects patients by limiting their first metatarsophalangeal range of motion (ROM) and also, their shoe wear. The objective of our work was to present an original operative technique which preserves the native joint and improves pain with minimal complications.METHODSWe conducted a retrospective multicenter cohort study of 28 patients (30 feet) suffering from moderate hallux rigidus, operated between October 2010 and October 2017 with at least 48months of follow-up. Clinical and radiological assessments included pre- and postoperative ROM, the American Orthopedic Foot and Ankle Society (AOFAS) score and forefoot radiological evaluation. No patients were lost to follow-up.RESULTSThe mean AOFAS score increased from 59 (range, 51 to 67) preoperatively to 84 (range, 80 to 88) at final follow-up. A total of 37 patients (97%) were satisfied. From a ROM point of view, this remained relatively unchanged between preoperative and postoperative values.CONCLUSIONThe percutaneous arthroscopically assisted cheilectomy combined with a percutaneous proximal phalanx osteotomy, significantly improves pain in hallux rigidus with index minus in patients with Coughlin stage I and II after a mean of 4-year follow-up.LEVEL OF EVIDENCEIV.

01 Dec 2024·The Journal of Allergy and Clinical Immunology: In Practice

Angioedema due to Acquired C1-Inhibitor Deficiency Associated With Monoclonal Gammopathies of Undetermined Significance Characteristics of a French National Cohort

Article

Author: Durupt, Francois ; Launay, David ; Adamski, Henri ; Roos-Weil, Damien ; Mekinian, Arsene ; Demoreuil, Claire ; Desblache, Julien ; Gondran, Guillaume ; Kalmi, Galith ; Defendi, Federica ; Gobert, Delphine ; Coppo, Paul ; Amarger, Stephanie ; Pelletier, Fabien ; Kanny, Gisele ; Gayet, Stephane ; Armengol, Guillaume ; Ly, Kim Heang ; Blanchard-Delaunay, Claire ; Bouillet, Laurence ; Caubet, Olivier ; Robbins, Aylsa ; Brihaye, Benoit ; Boccon-Gibod, Isabelle ; McAvoy, Chloé ; Lacoste, Marion ; Aubineau, Magali ; Martin, Ludovic ; Bibes, Beatrice ; Hadjadj, Jerome ; Lahuna, Constance ; Blaison, Gilles ; Cathebras, Pascal ; Fain, Olivier ; Ollivier, Yann

BACKGROUNDNo specific description of monoclonal gammopathies of undetermined significance (MGUS)-associated angioedema due to acquired C1 inhibitor deficiency (AAE-C1-INH) has been reported yet.OBJECTIVETo describe the biological and clinical characteristics, evolution, and response to treatment of MGUS-associated AAE-C1-INH.MATERIALS AND METHODSWe conducted a French national retrospective observational study on MGUS-associated acquired angioedema spanning a 30-year period.RESULTSForty-one patients with MGUS-associated AAE-C1-INH at diagnosis were included; 68% displayed anti-C1-INH antibodies. The monoclonal component was an IgM in 24 patients, IgG in 11, and IgA in 6 patients. The mean age at first angioedema attack was 63 years (standard deviation [SD] = 13 years) and at diagnosis 66 years (SD = 11 years). A total of 88% patients benefited from acute attack treatments, and 77% from long-term prophylaxis, either danazol, tranexamic acid, or lanadelumab. Median follow-up was 7 years, during which 14 patients (33%) evolved into well-defined malignant hemopathies. Fifty percent of patients were given a hematological treatment, either rituximab alone, indicated by recurrent attacks of angioedema in patients with AAE-C1-INH with anti-C1-INH antibodies, or validated combinations of chemotherapies, indicated by evolution into a lymphoma in 7 patients and a myeloma in 3 patients. Fifteen patients (35%) were in clinical complete remission of angioedema at last visit, of whom 60% had an undetectable serum monoclonal immunoglobulin.CONCLUSIONSComplete remission of AAE-C1-INH is correlated to complete remission of the underlying hematological malignancy, as defined by an undetectable serum monoclonal immunoglobulin. In our MGUS-associated acquired angioedema cohort, we recorded an incidence of evolution into hematological malignancy of 4% per patient-year. It is therefore crucial to conduct full hematological workup during follow-up at an annual rate, and earlier if AAE relapses or if acute attack frequency increases.

25 Nov 2024·Blood

Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Comparing Allogeneic Stem Cell Transplantation to Standard-Care in Children with Sickle Cell Anemia and History of Abnormal Cerebral Velocities

Author: Belozertseva, Catherine ; Bernaudin, Françoise ; Peffault de Latour, Regis ; Verlhac, Suzanne ; Pondarré, Corinne ; Paillard, Catherine ; Arnaud, Cecile ; Chantalat-Auger, Christelle ; Isabelle, Thuret ; Joseph, Laure ; Elmaleh, Monique ; Meunier, Benoit ; Neven, Benedicte ; Missud, Florence ; Jung, Camille ; Angoso, Marie ; Firah, Nadia ; Petras, Marie ; Dhédin, Nathalie ; Kamdem, Annie ; Yakouben, Karima ; Dalle, Jean-Hugues ; Guitton, Corinne ; Pertuisel, Sophie ; Genty, Isabelle ; Bruno, Bénédicte ; Cannas, Giovanna ; De Luna, Gonzalo ; Frange, Pierre ; Pluchart, Claire ; Ducros-Miralles, Elisabeth

AbstractDREPAGREFFE-1 (NCT01340404), was the first prospective trial comparing allogeneic stem cell transplantation (alloSCT) to standard-of-care (SoC) in children with sickle cell anemia (SCA). This French multicenter trial was defined by the random-availability of a matched-sibling donor (MSD). Inclusion criteria were SS/Sb0 children (5-15yr) placed on long-term chronic-transfusion (CT) for a history of abnormal cerebral arterial velocities (TAMMV≥200 cm/sec), with at least one non-SCA sibling, and parents accepting HLA-typing and alloSCT if an MSD was available.Sixty-seven children (35F/32M), including 7 with stroke-history, were enrolled (Dec-2010/June-2013). Children with MSD (n=32) were transplanted, while those without (n=35) were maintained on CT for at least one year and then switched to hydroxyurea (HU) if normalized TAMMVs and no stenosis. Results at 1 and 3 years were reported (Bernaudin et al JAMA. 2019;321(3); Verlhac et al Br J Haematol. 2021;193(1)). As a reminder, comparing alloSCT vs. SoC at 1 yr, the highest TAMMVs (primary outcome) were significantly lower after alloSCT than under SoC (difference -40.8 cm/s; [95%CI:-62.9;-18.6]; P<.001). At 3 years, the highest TAMMVs were lower, the proportion of patients with normalized-TAMMVs was higher, the stenosis score in stroke-free patients was lower, and the quality of life (QoL) was better for physical and school functioning. Nevertheless, no significant difference in ischemic lesions and cognitive performance was observed.DREPAGREFFE-2 trial (NCT 05053932), supported by ABM and Pfizer, aimed to reevaluate at 10yr the 67 SCA-children (Sept-2022/Aug-2024) to test whether the differences in cognitive performance and ischemic lesions had changed significantly. Events and treatment changes since Year 3 were routinely recorded. Clinical evaluation, routine biological check-up, Intracranial and cervical-color Doppler-ultrasound, cerebral MRI/MRA/neck-MRA were performed. Non-opposition consent was required for cognitive testing (WISC-V and WAIS-IV), biological research, and QoL (PedsQLTM) assessment. Death and stroke did not occur in either arm.In the alloSCT arm (n=32), follow-up ended at 7.0 and 7.9 years for 2 children with full donor-chimerism and no chGvHD, due to return to Africa and UK. At 10yr, median (range) donor-chimerism was 92.5% (19%-100%) and no chGvHD was observed.In the SoC arm (n=35), 23 patients with normalized velocities and no stenosis under CT were switched to HU. At 10yr, 17 are still on HU, 15 are on CT, and 3 had related haploIdentical-SCT at 6.7, 7.2 and 9.3yr post-enrollment. They are well, one having only mild chGvHD. Two patients still on CT for stroke-history did not give consent for research analyses.Including the 3 haplo-SCT with the alloSCT-arm for analysis at 10yr, Hb and HbA% were higher while HbS%, Retic., WBC, neutro, bilirubin, LDH, and ferritin were lower in the alloSCT vs. SoC arm (P<.001 for all).Available mean (SD) QoL at 10yr in alloSCT (n=25) vs. SoC (n=28) was not different for emotional but higher for physical (84.0 (16.3) vs 76.4 (11.2); P=.013), school (72.6 (17.2) vs 61.4 (14.7);P=.016) and even social functioning (93.8 (10.7) vs. 86.4 (12.9); P=.003).MRI/MRA and cognitive performance data were only analyzed in stroke-free patients. At enrollment (T0), silent cerebral infarcts (SCI) were present in 6/31 in the SoC-arm and 12/28 in the alloSCT arm. At 10yr, 5 additional patients had developed SCI in the SoC arm, but none did in the alloSCT, while SCI were either no more visible or <3mm in 1 (SoC) and 4 patients (alloSCT) (P=.010). Comparing alloSCT (n=24) to SoC (n=21), cognitive testing showed no difference in verbal comprehension and perceptual reasoning index, while the mean (SD) working memory index (WMI) was higher (89.6 (11.8) vs 80.5 (10.8); P=.021) with a digit span of 8.4 (1.9) vs. 6.7 (1.8)(P=.005), the processing speed index (PSI) was higher (96.5 (21.9) vs. 83.7 (14.4);P=.035) with a symbol search of 9.3 (2.0) vs. 7.3 (2.9)(P=.021), respectively. Compared to T0, mean (SD) WMI and PSI at 10yr improved, although not significantly, in transplanted patients [+5.8 (15.6) vs. +9.0 (25.4)] but not in the SoC arm [-2.0 (15.7) and +0.6 (19.7)].Thus, this first prospective comparative trial demonstrates that differences between alloSCT and SoC changed significantly at 10yr with alloSCT providing better primary prevention of SCI, social QoL, working memory and processing speed

100 Deals associated with Centre Hospitalier de Pau

100 Translational Medicine associated with Centre Hospitalier de Pau

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 09 Aug 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Centre Hospitalier de Pau

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 09 Aug 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing